| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
We have demonstrated the expression of Tim-3 and Galectin-9 in tumor cells from patients with breast cancer. No significant associations were identified between Tim-3 / Galectin-9 expression and cliniclo-pathological factors. The disease free survival were significantly shorter in the Tim-3-high group as compared with the Tim-3-low group (p=0.009).The disease free survival were significantly shorter in the Galectin-9-negative group as compared with the Galectin-9-positive group (p=0.008).On univariate analysis, the Tim-3 expression had a significant association with disease -free survival, lymphovascular invasion, HER2, low/absent of Galectin-9 expression and nuclear grade. Multivariate analysis demonstrated the significant role of Tim-3 expression in tumor cells as an independent prognostic factor for patients with breast cancer.
The status of Galectin-9 and Tim-3 could be determined on clinical examination and may have treatment value in the future.
|
